trending Market Intelligence /marketintelligence/en/news-insights/trending/rzet52cpnq31ui9-yt-tvg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

GlycoMimetics prices $119M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

GlycoMimetics prices $119M common stock offering

GlycoMimetics Inc. priced its previously announced public offering of 7 million shares at $17 each.

The Rockville, Md.-based biotechnology company expects to raise $119 million through the underwritten offering which is expected to close by March 23.

Jefferies and Cowen are acting as joint book-running managers for the offering, with Stifel and SunTrust Robinson Humphrey serving as co-lead managers.

Roth Capital Partners is acting as co-manager.

The underwriters have an option to buy up to an additional 1,050,000 shares at the offering price.

The company plans to use net proceeds to complete its phase 3 clinical development program for GMI-1271 in patients with acute myeloid leukemia. Proceeds will also be used for research and development, as well as working capital and general corporate purposes.